A fresh batch of commentary on PROCEPT BioRobotics (PRCT) is drawing attention to the stock after a recent summary highlighted rapid revenue scaling, expanding gross margins, and slightly lower management guidance.

Despite the fresh commentary around high revenue growth and expanding margins, PROCEPT BioRobotics’ share price return tells a different story. The stock is down 24.9% over 30 days and the 1 year total shareholder return has declined 63.9%, suggesting sentiment has cooled. At the same time, the latest 1 day move of 3.9% hints at interest returning around the revised guidance and growth narrative.

If this kind of volatility has you looking beyond a single surgical robotics stock, it may be a good moment to scan a wider set of robotics and automation opportunities using the Simply Wall St screener for 31 robotics and automation stocks

So with PROCEPT BioRobotics posting rapid revenue growth but the stock falling sharply over 1 year and now trading about 39% below the average analyst price target, is this a reset that creates an opportunity, or is the market already pricing in the next leg of growth?

Most Popular Narrative: 14% Undervalued

The main valuation narrative on PROCEPT BioRobotics pegs fair value at $25.26 per share, compared with the last close of $21.72. This frames the recent share price slide as a possible mismatch with fundamentals.

I have been an investor in PRCT since before IPO. The wild fluctuations in share price recently make no sense. The sell side analyst who chased the share price up to highs in 2024 (when the price was way too frothy) are doing the same thing now by revising the share price lower and lower, when clearly the company is still doing a great job. The recent downgrade by Leerink, citing PAE as a possible headwind for PRCT growth, is in direct opposition to what Larry Wood (CEO) stated at the last earnings call. To quote Larry Wood, “I don’t think PAE is a headwind for us at all. I think PAE is a big red herring. It’s a procedure that really does not get performed in any volume in Europe. And the reason it doesn’t get performed is because it doesn’t get paid for because it’s not a very good procedure.” So if you believe Larry Wood, then the company has been grossly oversold and looks very very cheap down here. If PRCT hit the Q2 numbers watch all the sheep suddenly revise their target prices back up again. I think fair value is still up at $47. PRCT had a reassessment of how to report handpiece sales versus procedures and therefore there was a shortfall on revenue. Clearly they could have stuck with the old model and revenue would have been better. Larry is doing a great job of making reporting a direct reflection of procedures being done. If the numbers are delivered, watch this thing fly.

Want to see how this narrative gets to a higher fair value than today’s price, even while PRCT remains loss making? The key ingredients are strong top line growth assumptions, a future profit margin target that shifts the business toward double digit profitability, and a valuation multiple usually associated with established medtech platforms. Curious how those moving parts fit together and what has to happen for that $25.26 fair value to stack up over time? Read on in the full narrative to see the numbers behind the story.

Result: Fair Value of $25.26 (UNDERVALUED)

However, PROCEPT BioRobotics still carries clear risks, including its ongoing net losses and the possibility that future procedure volumes or pricing do not match bullish assumptions.

Next Steps

With sentiment clearly split on PROCEPT BioRobotics, this is a moment to move quickly, review the underlying data yourself and decide where you stand using the 1 key reward and 1 important warning sign

Looking for more investment ideas beyond PROCEPT BioRobotics?

If PROCEPT BioRobotics has sharpened your focus on where to put fresh capital, do not stop here. Broaden your watchlist with a few targeted stock ideas.

• Spot potential mispricings early by scanning 45 high quality undervalued stocks that combine robust fundamentals with prices that may not fully reflect their underlying financial strength.
• Prioritise resilience by reviewing 66 resilient stocks with low risk scores that score well on balance sheet strength and business stability for a smoother portfolio ride.
• Hunt for tomorrow’s potential standouts with the screener containing 19 high quality undiscovered gems, focusing on companies that have solid fundamentals but limited current market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.